Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Pharma Mar is a Spanish biotech company that discovers and sells cancer drugs derived from sea organisms.
Pharma Mar is a Spanish drug company that turns sea creatures into cancer medicine. Its most important product is Yondelis, a treatment for certain soft-tissue cancers and ovarian cancer that originally came from a sea squirt, a strange little filter-feeding animal found on the ocean floor. The company discovers these molecules, runs clinical trials, manufactures the drugs, and sells them through partners and its own sales force in countries around the world.
The business is unusual because most of its raw material comes from the sea rather than a chemistry lab. Pharma Mar has spent decades collecting marine organisms and testing their chemical defenses, since a creature that survives in the ocean often carries potent compounds. Two of its approved drugs, Yondelis and Aplidin, came out of that effort. It also has a pipeline of experimental cancer drugs in various stages of testing, which is the long, expensive, uncertain part of the biotech game: years of trials, regulatory hurdles, and the real chance that most candidates fail. Pharma Mar sells mostly to hospitals and cancer treatment centers, either directly or through larger pharmaceutical partners who handle distribution in certain regions. Its revenue depends heavily on how many patients receive its approved drugs and on milestone and royalty payments from those partners. That makes the business lumpy and exposed to competition from other cancer treatments, plus the constant pressure of price negotiations with health systems.
The company is headquartered near Madrid, and it stands out in Spanish biotech for doing original discovery research rather than just making generic copies of off-patent drugs. The big question for investors is straightforward: can its pipeline produce another approved blockbuster before the patents on its existing drugs run out? That is the gamble every research-driven drug company lives with.
Saved answer 路 last researched 15 Nov 2026